Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.It's a big week for FDA advisory committee meetings. ... Show More
Sep 24
The FDA's Overton era, and dispatches from Shanghai
"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development means for the biotech industry. The hosts also speak to colleague Margaret Manto about Heidi Overton, the pres ... Show More
29m 41s
Sep 17
Definium's new psychedelics data, and a reprieve for international scientists
International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the latest news in the life sciences, on this we ... Show More
28m 17s
Dec 2023
Bristol’s $14 Billion Karuna Deal Highlights Race for New Drugs
Laura Chico, Biotechnology Research Analyst at Wedbush Securities and Bloomberg News US Deals Team Leader Matthew Monks share their thoughts on the Bristol Myers acquisition Karuna Therapeutics. John Mowrey, CIO at NFJ Investment Group, explains where to find value in the markets ... Show More
1h 2m